Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M70,744Revenue $M8,264Net Margin (%)11.2Z-Score2.6
Enterprise Value $M85,023EPS $2.7Operating Margin %24.8F-Score6
P/E(ttm))84.8Cash Flow Per Share $4.9Pre-tax Margin (%)13.4Higher ROA y-yY
Price/Book14.010-y EBITDA Growth Rate %10.5Quick Ratio1.2Cash flow > EarningsY
Price/Sales9.55-y EBITDA Growth Rate %55.9Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %148ROA % (ttm)3.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)18.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M336ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 210.4236%Reduce -6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 210.4236%Reduce -24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 210.4236%Reduce -18.50%1,378,606
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 210.4236%New holding295,632
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 210.4236%Reduce -0.47%34,331,973
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 210.4236%Reduce -1.19%1,794,227
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 210.4243%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 210.4243%Add 12.40%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 210.4243%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 210.4243%Add 8.89%10,985,940
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 210.4243%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 210.4243%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 210.4243%Add 0.57%34,494,015
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 210.4243%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 210.4239%Add 8.19%6,050,442
VRXSteve Mandel 2014-06-30 Add0.64%$116.99 - $138.13
($127.6)
$ 210.4239%Add 14.44%10,089,450
VRXJohn Paulson 2014-06-30 Reduce-0.32%$116.99 - $138.13
($127.6)
$ 210.4239%Reduce -49.97%500,300
VRXGeorge Soros 2014-06-30 Add0.29%$116.99 - $138.13
($127.6)
$ 210.4239%Add 185.46%472,187
VRXWallace Weitz 2014-06-30 Reduce-0.19%$116.99 - $138.13
($127.6)
$ 210.4239%Reduce -2.91%1,551,076
VRXChris Davis 2014-06-30 Add0.17%$116.99 - $138.13
($127.6)
$ 210.4239%Add 16.03%3,153,748
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.014.69view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4830.48view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0649.5view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.7343.68view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7343.68view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.9527.72view
Farmer, RonDirector 2014-11-24Buy1,000$163.9527.72view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2547.2view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.772.05view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.772.05view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
    The Top Guru-Held Canadian Stocks Apr 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    Pershing Square Holdings: First Annual Report Mar 25 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
    Ruane, Cunniff & Goldfarb’s Sequoia Fund Q4 2014 Shareholder Letter Mar 16 2015 
    Ruane Cunniff Sells Portions of Five of its Top 10 Stakes Mar 13 2015 


    More From Other Websites
    Will the Salix-Valeant story play out over and over again? Apr 23 2015
    LLY CFO: Here's what's driving profits Apr 23 2015
    Meet Pharma’s Newest Movers and Shakers Apr 22 2015
    Lone Pine Reduces Its Stake in Valeant Pharmaceuticals Apr 22 2015
    Are M&A Replacing R&D In Pharma? Apr 22 2015
    Mylan plays monkey-in-the-middle of hostile takeover battles Apr 21 2015
    Teva Pharmaceutical offers to buy Mylan for $40.1 bn Apr 21 2015
    Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog Apr 21 2015
    Teva Pharmaceuticals Hopes $40 Billion Mylan Deal Will Fuel Stock Rebound Apr 21 2015
    Billionaire Andreas Halvorsen’s New Healthcare Pick Apr 20 2015
    Will St. Jude Medical's (STJ) Earnings Miss the Mark in Q1? - Analyst Blog Apr 20 2015
    Microsoft Corporation (MSFT), Valeant Pharmaceuticals Intl Inc (VRX): Partner Fund Management’s... Apr 18 2015
    Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog Apr 17 2015
    Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015
    Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies? Apr 17 2015
    Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog Apr 16 2015
    Does Curtis Macnguyen really avoid hedge fund hotels? Apr 16 2015
    Amgen Gets FDA Nod for Chronic Heart Failure Drug Corlanor - Analyst Blog Apr 16 2015
    Conatus Pharmaceuticals Inc (CNAT): Healthcor Takes Large Stake; See Conatus’ Needham Healthcare... Apr 16 2015
    Valeant Pharmaceuticals (VRX), CBS Corporation (CBS) and Sirius XM Holdings (SIRI) Pushed This... Apr 16 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK